125 related articles for article (PubMed ID: 11422606)
21. Association of drug levels & pharmacokinetics of carbamazepine with seizure control.
Vasudev A; Tripathi KD; Puri V
Indian J Med Res; 2000 Dec; 112():218-23. PubMed ID: 11247200
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.
Ahmed GF; Brundage RC; Marino SE; Cloyd JC; Leppik IE; Pennell PB; Ramsay RE; Birnbaum AK
J Clin Pharmacol; 2013 Mar; 53(3):276-84. PubMed ID: 23408495
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.
Rivas N; Buelga DS; Elger CE; Santos-Borbujo J; Otero MJ; Domínguez-Gil A; García MJ
Ther Drug Monit; 2008 Aug; 30(4):483-9. PubMed ID: 18641550
[TBL] [Abstract][Full Text] [Related]
25. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
Mawer GE; Jamieson V; Lucas SB; Wild JM
Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers.
Shahzadi A; Javed I; Aslam B; Muhammad F; Asi MR; Ashraf MY; Zia-ur-Rahman
Pak J Pharm Sci; 2011 Jan; 24(1):63-8. PubMed ID: 21190921
[TBL] [Abstract][Full Text] [Related]
27. Iron supplements in nursing home patients associated with reduced carbamazepine absorption.
Ahn JE; Bathena SPR; Brundage RC; Conway JM; Leppik IE; Birnbaum AK
Epilepsy Res; 2018 Nov; 147():115-118. PubMed ID: 30327119
[TBL] [Abstract][Full Text] [Related]
28. A pharmacodynamic approach to the estimate of carbamazepine autoinduction.
Scheyer RD; Cramer JA; Mattson RH
J Pharm Sci; 1994 Apr; 83(4):491-4. PubMed ID: 8046601
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
31. [Tolerance of high dosage carbamazepine monotherapy in treatment of epilepsy].
Bauer J; Hermann A; Reuber M
Nervenarzt; 2002 Jun; 73(6):533-7. PubMed ID: 12243000
[TBL] [Abstract][Full Text] [Related]
32. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of carbamazepine in adults with epilepsy.
Graves NM; Brundage RC; Wen Y; Cascino G; So E; Ahman P; Rarick J; Krause S; Leppik IE
Pharmacotherapy; 1998; 18(2):273-81. PubMed ID: 9545146
[TBL] [Abstract][Full Text] [Related]
34. Validation of a quick modeling program generating clearance estimates at steady state for routine therapeutic drug monitoring.
el Battah A; Beglia S; Alric R
Ther Drug Monit; 1995 Aug; 17(4):348-55. PubMed ID: 7482688
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.
Reith DM; Hooper WD; Parke J; Charles B
J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):79-92. PubMed ID: 11253616
[TBL] [Abstract][Full Text] [Related]
36. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
37. Lack of interaction of gabapentin with carbamazepine or valproate.
Radulovic LL; Wilder BJ; Leppik IE; Bockbrader HN; Chang T; Posvar EL; Sedman AJ; Uthman BM; Erdman GR
Epilepsia; 1994; 35(1):155-61. PubMed ID: 8112239
[TBL] [Abstract][Full Text] [Related]
38. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers.
Bedada SK; Appani R; Boga PK
Drug Res (Stuttg); 2017 Jan; 67(1):46-51. PubMed ID: 27776366
[TBL] [Abstract][Full Text] [Related]
39. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite.
Wang RB; Liu LT; Yiu CH; Chang TY
Zhonghua Yi Xue Za Zhi (Taipei); 1990 Apr; 45(4):222-32. PubMed ID: 2168269
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
